BioMarin Pharma (BMRN) Tops Q3 EPS by 5c; Raises Outlook

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/13/2026

1. WDAY
2. AAPL
3. JNJ
4. META
5. NRIX
6. SUNS
7. SNDX
8. OIG
9. ACI
10. MRVL

Go back to BioMarin Pharma (BMRN) Tops Q3 EPS by 5c; Raises Outlook

BioMarin Announces Third Quarter 2015 Financial Results and Company Update

October 29, 2015 4:03 PM EDT

- Vimizim Net Product Revenue $65 million in the Quarter; Vimizim Full-year Revenue Guidance Increased to $220 to $235 million

- Full-year Total BioMarin Revenue Guidance Increased to $880 million to $900 million

- FDA Advisory Committee to Review Kyndrisa (drisapersen) November 24th for Treatment of Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping

Financial Highlights ($ in millions, except per share data, unaudited) 

 Three MonthsEnded September... More